ADVA
6.12.2019 09:02:05 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Play has deployed its Oscilloquartz timing solution to provide LTE Advanced services throughout Poland and prepare its network for 5G. The PTP grandmaster with dual integrated GNSS antenna enables Play to deliver the resilient and accurate Precision Time Protocol (PTP) frequency and phase synchronization needed for next-generation connectivity. With its ultra-compact design, the OSA 5405 Series empowers Play to migrate its radio access network from costly GNSS RF antennas and coax cables to standard copper and fiber Ethernet cabling, dramatically reducing capital expenditure and operating expenses. ADVA’s long-term partner NAVI also played a key role in the project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005008/en/
“This deployment is about taking our RAN infrastructure to the next level. ADVA’s versatile and compact devices are easy to install in a wide range of outdoor locations. And, with low-touch provisioning and power over Ethernet, installation is even simpler and more cost-effective,” said Michał Ziółkowski, CTO, Play. “This solution delivers the extremely precise timing required for next-generation connectivity. With the OSA 5405 ensuring accurate and robust phase synchronization, we can offer unique LTE Advanced services and prepare for the 5G future.”
Built on the environmentally hardened outdoor variant of the OSA 5405 Series, Play’s new synchronization architecture delivers IP-based frequency and phase synchronization. This ensures ultra-precise timing with no jitter or delay, supporting advanced applications and enhanced user experience. The OSA 5405 Series supports every major GNSS constellation – GPS, BEIDOU, GLONASS and GALILEO – as well as multiple protection options from PTP to SyncE. And, with its compact and environmentally friendly design, it ensures accurate time distribution with the smallest size and power footprint on the market.
“As Poland’s leading mobile communication service provider, it was vital that Play optimized its RAN infrastructure. With our technology ensuring maximum spectral efficiency, Play can provide increased value today and, at the same time, lay down the foundation for the next stage of mobile connectivity,” commented Ardashes Garabedian, senior sales manager, Eastern Europe and CIS, ADVA. “Our easy-to-deploy OSA 5405 Series is the ideal solution to seamlessly and affordably evolve Play’s existing timing architecture to IP-based synchronization. It minimizes complexity and power requirements as well as installation and operating costs. This solution significantly enhances mobile service quality of experience and opens the door to emerging IoT use cases and 5G.”
“Our agile OSA 5405 Series makes the task of bringing precise phase synchronization to the edge of Play’s mobile network simple and cost-efficient. With its ruggedized design and minimal visibility, it can be easily installed in almost any outdoor location,” said Gil Biran, general manager, Oscilloquartz. “Our OSA 5405 Series brings precise sync to built-up areas and urban canyons and, with its low-touch provisioning and plug-and-play features, it ensures straightforward configuration and maximum scale.”
“When it comes to synchronizing packet networks, our engineers offer a wealth of experience and expertise,” said Olaf Frączyk, CTO, NAVI. “We are proud to be part of this network upgrade, helping Play to unleash the full potential of its network. Working closely with our trusted partner ADVA, we’ve created a solution that ensures highly efficient spectrum utilization and unbeatable network performance both now and in years to come.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com
.
About PLAY
PLAY is the leading mobile phone network in Poland, with over 15 million subscribers. The PLAY network is operated by P4 sp. z o.o. whose main shareholder is Play Communications SA – a company listed on the Warsaw Stock Exchange. The company provides mobile voice, text, data and video services to individual and business clients (including, first and foremost, small and medium-sized enterprises), on the basis of contracts or in the pre-paid model, under the PLAY umbrella brand. The services offered by the operator are available to 99% of the Polish population thanks to PLAY’s own, extensive and modern telecommunications network (2G/3G/4G LTE/5G Ready) and the national roaming service. More information can be found at www.playcommunications.com
and www.play.pl
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191206005008/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
